CENTOGENE prices initial public offering

Centogene (CNTG) has priced its initial public offering of 4M common shares at $14/share, for total gross proceeds of ~$56M.

Underwriters over-allotment is an additional 600K common shares.

The shares are scheduled to begin trading today on the Nasdaq Global Market and the offering is expected to close on November 12.

https://seekingalpha.com/news/3516097-centogene-prices-initial-public-offering

DENTSPLY SIRONA EPS beats by $0.07, beats on revenue

DENTSPLY SIRONA (NASDAQ:XRAY): Q3 Non-GAAP EPS of $0.57 beats by $0.07; GAAP EPS of $0.38 beats by $0.04.

Revenue of $962M (+3.7% Y/Y) beats by $21.62M.

Shares -2.3% PM.

Press Release

https://seekingalpha.com/news/3516117-dentsply-sirona-eps-beats-0_07-beats-revenue

Karuna Therapeutics EPS beats by $0.08

Karuna Therapeutics (NASDAQ:KRTX): Q3 GAAP EPS of -$0.39 beats by $0.08.

Cash, equivalents and short-term investments of $161.61M

Press Release

https://seekingalpha.com/news/3516138-karuna-therapeutics-eps-beats-0_08

Athenex EPS in-line, beats on revenue

Athenex (NASDAQ:ATNX): Q3 GAAP EPS of -$0.45 in-line.

Revenue of $19.36M (+5.0% Y/Y) beats by $4.75M.

Press Release

https://seekingalpha.com/news/3516220-athenex-eps-line-beats-revenue

Axsome Therapeutics EPS misses by $0.16

Axsome Therapeutics (NASDAQ:AXSM): Q3 GAAP EPS of -$0.56 misses by $0.16.

Cash of $43.64M

Shares -0.1%

Press Release

https://seekingalpha.com/news/3516232-axsome-therapeutics-eps-misses-0_16

Lexicon Pharmaceuticals EPS beats by $1.41, beats on revenue

Lexicon Pharmaceuticals (NASDAQ:LXRX): Q3 GAAP EPS of $1.95 beats by $1.41.

Revenue of $294.4M (+4105.7% Y/Y) beats by $282.4M.

Press Release

https://seekingalpha.com/news/3516223-lexicon-pharmaceuticals-eps-beats-1_41-beats-revenue

AmerisourceBergen top line up 5%, earnings off 32%

AmerisourceBergen (NYSE:ABC) fiscal Q4 results:

Revenue: $45,637.8M (+5.4%); Pharmaceutical Distribution Services: $43,865.4M (+5.1%).

Net income: $132.3M (-31.8%); non-GAAP net income: $338.2M (+7.3%); EPS: $0.63 (-41.1%); non-GAAP EPS: $1.61 (+11.0%).

Cash flow ops (FY): $2,344.0M (+66.1%).

Fiscal 2020 guidance: Revenue growth: Mid-to-high single digit; non-GAAP operating income growth: low-to-mid-single digit; non-GAAP free cash flow: ~$1.5B.

Previously: AmerisourceBergen EPS beats by $0.03, beats on revenue (Nov. 7)

https://seekingalpha.com/news/3516243-amerisourcebergen-top-line-5-percent-earnings-32-percent